In the last four decades, India has funded biotech research institutions but now sees that it needs to be going beyond and setting up companies, in public private partnership mode, to bolster biotechnology manufacturing. There are six verticals that this initiative envisages: bio-based chemicals and enzymes; functional foods and smart proteins; precision biotherapeutics; climate-resilient agriculture; carbon capture, and futuristic marine and space research. Futurists have been saying that the era of fossil-fuel industrialisation is over and humanity will have to rely on the natural world — for food and for making consumer products. This is to solve the global problem of non-biodegradable waste and carbon emissions. Future industries must be grounded in environmentally benign products, and this is impossible without sophisticated biotechnology. By setting up bio-foundries and bio-artificial intelligence hubs, the policy hopes there will be avenues for a variety of biotechnologists to congregate. Well intentioned this may be, but India’s woes with manufacturing have chronic causes. Without establishing enabling grounds for long-term capital investment — and these have little to do with biotechnology per se — top-down initiatives will have limited impact. The BioE3 policy must be a deeply collaborative effort between Centre and States. Rather than expect quick returns, the government must provide financial and infrastructural support over the long term.